= Hepatitis B Vaccine at Birth <ch-hepatitis-b>

== One-Page Overview

The hepatitis B vaccine has been given to newborns in the United States for over 30 years. In December 2025, the CDC changed its recommendation: for babies born to mothers who test negative for hepatitis B during pregnancy, the birth dose is now an individual decision rather than a universal recommendation. This opens the door to vaccinating at birth, delaying, or declining — depending on your family's situation and values.

This change has sparked controversy. The American Academy of Pediatrics called it "irresponsible" and continues to recommend the birth dose for all newborns. New York State rejected the new guidance entirely.

*The bottom line:* If you test negative for hepatitis B during pregnancy, you have options — vaccinate at birth, delay to 2 months or later, or decline entirely. Each is an informed decision with its own rationale. This chapter lays out the full picture so you can choose what fits your family.

#line(length: 100%)

== What Is Hepatitis B?

Hepatitis B is a viral infection that damages the liver. Unlike a brief illness that comes and goes, hepatitis B can establish a lifelong infection in the body if it is not cleared by the immune system.

=== How It Spreads

Hepatitis B spreads when blood or body fluids from an infected person enter someone else's body. The main routes are:

- *Blood exposure:* Through needlestick injuries, shared needles, or contact with infected blood through cuts or sores
- *Sexual transmission:* The most common route for adults in developed countries
- *Mother-to-child (perinatal):* During pregnancy, labor, or delivery—this is the primary concern for newborns
- *Household contact:* The virus can survive on surfaces for more than 7 days, so transmission can occur through shared personal items like toothbrushes or razors if they contain infected blood

=== Why Infants Are Especially Vulnerable — If Exposed

Here is an important fact about hepatitis B and babies: *approximately 90% of infants infected at birth develop chronic lifelong infection.*

This is dramatically different from adults. When an adult catches hepatitis B, their immune system typically fights it off within six months. Only 2-6% of infected adults develop chronic infection.

Babies' immune systems are less effective at clearing the virus. This 90% chronic infection rate is the main reason the birth dose has been recommended for three decades.

*The critical qualifier:* This 90% figure applies only to infants who are actually exposed to hepatitis B — primarily those born to HBV-positive mothers. If a mother tests negative, the baby has no exposure at birth, and this statistic does not apply to them.

=== What Chronic Infection Means

Chronic hepatitis B means the virus stays in the body indefinitely. Many children with chronic infection feel fine and grow normally for years. But the virus causes slow, progressive liver damage over decades.

Long-term consequences include:
- *Cirrhosis:* Scarring of the liver that can lead to liver failure
- *Liver cancer:* Hepatitis B is the second most common cause of cancer worldwide after tobacco
- *Early death:* About 15-25% of people infected at birth will die from liver disease if untreated

#line(length: 100%)

== The 2025 Policy Change

=== What ACIP Now Recommends

On December 16, 2025, the CDC formally adopted a new approach to the hepatitis B birth dose. Here is what changed:

*For babies born to mothers who test positive for hepatitis B or whose status is unknown:*
- Nothing changed. These babies should receive the hepatitis B vaccine AND hepatitis B immunoglobulin (HBIG) within 12 hours of birth.

*For babies born to mothers who test negative during pregnancy:*
- Parents and providers can now decide together whether to give the vaccine at birth or begin the series at the 2-month visit.

This represents a shift from universal recommendation to individual decision-making for one specific group: babies born to mothers with confirmed negative test results.

=== What This Means for You

If you are pregnant and test negative for hepatitis B, you have a decision to make: vaccinate at birth, delay, or decline. The CDC's 2025 change explicitly acknowledges that this is an individual decision for HBV-negative mothers.

If your hepatitis B status is unknown or positive, the medical recommendation is clear: the vaccine (and HBIG if you are positive) within 12 hours of birth.

#line(length: 100%)

== The Case for the Birth Dose

=== The 90% Chronic Infection Risk

The most compelling argument for the birth dose is simple math: if a newborn is exposed to hepatitis B and not vaccinated, there is a 9 in 10 chance they will develop lifelong infection with serious consequences.

The birth dose prevents infection at the moment of greatest vulnerability.

=== Catch-Up for Missed Screening

The birth dose serves as a safety net for gaps in prenatal screening. While screening is highly accurate, it is not perfect:
- Research suggests 10-16% of pregnant people are not tested for hepatitis B during pregnancy
- Some mothers deliver in settings where prenatal records are unavailable
- Early screening rates are lower, with only 60% of commercially insured and 39% of Medicaid-enrolled women tested in the first trimester

For mothers who were not adequately screened, the birth dose provides immediate protection.

=== Household Transmission Protection

Even if you test negative, the vaccine protects against an unknown risk: household members who may have hepatitis B without knowing it. About 50% of people in the United States with hepatitis B are unaware of their infection. If an undiagnosed household member transmits the virus through blood contact, a vaccinated infant would be protected.

=== Decades of Observational Safety Data

The hepatitis B vaccine has been administered to millions of newborns over 30+ years. The CDC has not detected unexpected safety signals through its surveillance systems. (For a fuller discussion of what "safety data" means in context — including trial design, VAERS, and aluminum adjuvant questions — see the Safety Profile section below.)

=== The AAP's Position

The American Academy of Pediatrics, the nation's largest pediatrician organization, strongly opposes the 2025 change. They call the new guidance "irresponsible" and "purposely misleading." The AAP continues to recommend routine hepatitis B vaccination for all newborns without delay.

It is worth noting that the AAP receives significant funding from vaccine manufacturers and that organizational positions reflect institutional consensus, not unanimous agreement among pediatricians. Many individual pediatricians support parental choice on this issue.

#line(length: 100%)

== The Case for Delaying

=== If Mom Is Hepatitis B Negative: Zero Risk at Birth

The central argument for allowing delay is straightforward: perinatal transmission happens when a mother has hepatitis B and transmits the virus to her baby during pregnancy, labor, or delivery. If the mother does not have hepatitis B, this route cannot occur.

*For a baby born to a mother with a confirmed negative test, the risk of perinatal transmission is zero.* Not low. Zero. You cannot transmit what you do not have.

=== Reliability of Prenatal Screening

The test for hepatitis B (called HBsAg) has sensitivity and specificity greater than 98%. This means:
- If you test positive, you almost certainly have hepatitis B
- If you test negative, you almost certainly do not

A negative test is genuinely reassuring. The CDC committee relied heavily on this accuracy when making the 2025 change.

=== Understanding How Hepatitis B Actually Spreads

Hepatitis B is transmitted through blood-to-blood contact and sexual contact. These routes are simply not relevant for newborns in typical family situations.

For a newborn with a hepatitis B-negative mother:
- *No perinatal transmission* (mother doesn't have the virus)
- *No sexual transmission* (irrelevant for infants)
- *Household transmission requires* an infected household member with blood exposure

The only realistic risk is if an undiagnosed household member has hepatitis B and there is blood contact (shared toothbrush, contact with open wounds, etc.). This risk is real but quite low in the United States, where hepatitis B prevalence is less than 1%.

=== Why Was Universal Birth Vaccination Adopted?

The birth dose was adopted in 1991 not because all newborns face immediate risk, but for two practical reasons:

1. *To catch babies whose mothers were not tested or tested falsely negative* (the "safety net" argument)
2. *Because newborns in the hospital represent a "captive audience"* where vaccination can be reliably administered before discharge

The second reason is particularly important to understand. The birth dose was chosen partly because it guarantees vaccination happens—not because there is medical urgency for day-one protection in babies born to hepatitis B-negative mothers.

=== Concerns About Waning Immunity

One concern raised during the 2025 ACIP vote was that vaccine immunity may wane over time. ACIP member Dr. Meissner noted that "giving one dose and then letting a child become susceptible later in subsequent years" could represent harm.

This raises a valid question: *if you vaccinate at birth, will immunity last through adolescence and adulthood when actual risk begins?*

Some research suggests antibody levels decline over time, though cellular immunity may provide longer protection. This is an area of ongoing research and legitimate debate.

=== International Perspective: Other Developed Countries Do Not Universally Vaccinate at Birth

The ACIP committee explicitly noted that *"the United States' universal recommendation of the hepatitis B vaccine birth dose was an outlier among developed countries with low hepatitis B prevalence."*

Examples:
- *Japan:* Universal hepatitis B vaccination begins at 2 months (except for babies of HBV-positive mothers, who receive the birth dose)
- *Sweden:* Universal vaccination begins at 3 months (except for babies of HBV-positive mothers, who receive the birth dose)
- *United Kingdom:* Universal vaccination begins at 8 weeks
- *Many European countries:* Begin the series at 6 weeks to 3 months

These countries achieve excellent hepatitis B protection without universal birth dosing. They use risk-based birth dosing (for babies of infected mothers) and universal vaccination starting at 2-3 months.

=== Delaying to the 2-Month Visit

Delaying the birth dose is not the same as skipping the vaccine. The vaccine series can still be completed with the same three-dose schedule, just starting at 2 months instead of birth.

Many developed countries use schedules that begin at 6 weeks to 3 months of age and achieve excellent protection rates. If you defer the birth dose, your baby can begin the series at 2 months with full immunity still achievable.

#line(length: 100%)

== The Case for Declining Entirely

Some families choose not only to delay the hepatitis B vaccine but to decline it altogether — or to delay it well beyond the infant schedule. This is an informed decision, not negligence, and it deserves the same respectful treatment as any other choice in this chapter.

=== The Reasoning Families Cite

Parents who decline or significantly delay the hepatitis B vaccine typically weigh several factors:

- *Low-risk baby:* Both parents have tested negative for hepatitis B. The virus is transmitted through blood and sexual contact — routes that are not relevant to a newborn or young child in a typical household.
- *Concerns about the newborn immune system:* Some parents prefer not to introduce vaccines (and their adjuvants) during the first hours or months of life, when the immune system is still developing.
- *Aluminum adjuvant content:* The hepatitis B vaccine contains aluminum hydroxide. Some families have concerns about injecting aluminum into a newborn. (See the Aluminum Adjuvant section below for a full discussion.)
- *Desire to delay or space out all vaccines:* Many families who decline the birth dose are not anti-vaccine — they prefer an alternative or delayed schedule.
- *Questioning the risk-benefit ratio:* For a disease the baby has essentially zero chance of encountering if both parents are HBV-negative, some families conclude the known (even small) risks of any medical intervention outweigh the theoretical benefit.

=== Transmission Risk in Context

Hepatitis B is not airborne. It is not spread through casual contact, coughing, sneezing, breastfeeding, sharing food, or hugging. It spreads through blood-to-blood contact and sexual contact.

For a newborn with two HBV-negative parents:
- *Perinatal transmission:* impossible (the mother does not carry the virus)
- *Sexual transmission:* not applicable
- *Household blood contact:* would require an undiagnosed HBV-positive household member AND direct blood-to-blood exposure — an extremely unlikely scenario in a low-prevalence country

This is why parents who test negative for HBV can make a rational, evidence-based case that their newborn faces effectively zero risk of hepatitis B exposure during infancy and early childhood.

=== This Is a Legitimate Informed Decision

Declining or significantly delaying the hepatitis B vaccine for a low-risk baby is not the same as ignoring a real and present danger. It is a judgment call about whether to provide medical intervention against a disease the child is extremely unlikely to encounter.

Reasonable people can — and do — come to different conclusions. Some families will vaccinate at birth because they value the safety net. Others will decline because the risk does not apply to their situation. Both are valid positions grounded in the same set of facts.

=== Timing Alternatives Beyond 2 Months

Your options are not limited to "birth dose" or "2-month dose." Families who decline or delay may consider:

- *Delay to school age (4-6 years):* Some families wait until the child is older and the immune system is more mature, then vaccinate before school entry when some states require it
- *Delay to pre-adolescence (11-12 years):* Since actual hepatitis B risk for most people begins with sexual activity and potential blood exposure, some families choose to vaccinate before the teenage years
- *Selective vaccination based on risk factors:* If circumstances change (international travel to high-prevalence areas, new household members with unknown status, etc.), vaccination can be initiated at any point
- *Decline entirely:* Some families choose not to vaccinate for hepatitis B at all, particularly if they believe their child's lifetime risk profile remains very low

Each of these is a complete and defensible position for a family that has done the research.

#line(length: 100%)

== Transmission: How Would Baby Get It?

Understanding exactly how hepatitis B spreads to newborns helps clarify the decision.

=== Mother-to-Child (The Primary Concern)

This is why the birth dose exists. Without intervention:
- Babies born to mothers with high viral loads have a 70-90% chance of infection
- Babies born to mothers with lower viral loads have a 5-20% chance of infection

With the vaccine and HBIG at birth, effectiveness is 94% even for exposed infants.

*Critical point:* If the mother tests negative for hepatitis B, mother-to-child transmission cannot occur. The virus is not there to transmit.

=== Other Routes

*Household transmission:* If a household member is infected (even unknowingly), transmission is possible through blood contact from minor cuts, sores, or shared personal items. This risk is real but relatively small in developed countries with low hepatitis B rates.

*Other routes* (sexual transmission, needlestick injuries) are not relevant for typical newborn circumstances.

#line(length: 100%)

== Safety Profile

=== What Observational Data Shows

The hepatitis B vaccine has been given to millions of newborns over 30+ years. Population-level surveillance has found:

- No detected link to serious adverse outcomes including neonatal death, seizures, or neurological disorders
- No detected association with autoimmune conditions like multiple sclerosis (despite concerns raised in 1998)
- A comprehensive review of at least 12 million doses found no serious health problems linked to the vaccine
- Even in vulnerable preterm infants, the observational safety record is reassuring

=== Common Reactions

Most infants have no side effects or only mild, temporary reactions:
- *Injection site soreness or redness:* 8-20% of newborns (rarely severe)
- *Fever:* 0-6% of newborns (rarely severe)
- *Mild fussiness:* Typically resolves in 1-2 days

=== Serious Adverse Events

Severe reactions are uncommon but do occur:
- *Anaphylaxis* (severe allergic reaction): Approximately 1 per 600,000 doses
- When anaphylaxis occurs, it happens quickly, medical staff are present, and it responds well to treatment
- Death from vaccine-related anaphylaxis is extraordinarily rare

=== Safety Testing: What Was and Was Not Done

Most parents assume that when they are told a vaccine is "proven safe," it has been tested the way a new drug would be — with a double-blind, placebo-controlled trial where one group gets the vaccine and another gets an inert placebo (like saline). This is not how most childhood vaccines, including the hepatitis B vaccine, were tested.

In the clinical trials for the hepatitis B vaccine, the control groups typically received another vaccine or an aluminum-containing solution — not a true inert placebo. This is standard practice in vaccine research: once a vaccine is considered effective, giving a control group nothing is viewed as unethical by institutional review boards.

*What this means:*
- The vaccine has strong evidence of *effectiveness* — it clearly prevents hepatitis B infection
- The vaccine has extensive *observational* safety data from decades of population-level surveillance
- What it does not have is a pre-licensure trial comparing vaccinated newborns to completely unvaccinated newborns using an inert placebo to isolate the vaccine's effects on health outcomes
- This does not prove the vaccine is unsafe. But it means the type of safety evidence is different from what most parents assume when they hear "proven safe"

*The precautionary principle:* For a disease a newborn is extremely unlikely to encounter (if parents are HBV-negative), some families weigh the known versus unknown risks differently. They may conclude that the absence of true placebo-controlled safety data — combined with the near-zero risk of exposure — tips the balance toward declining or delaying. Others find the decades of observational data entirely sufficient. Both positions are defensible.

=== Aluminum Adjuvant

The hepatitis B vaccine contains aluminum hydroxide as an adjuvant — a substance added to stimulate a stronger immune response. This is one of the most common questions parents raise.

*The facts:*
- Each dose of the hepatitis B vaccine contains approximately 250 micrograms (0.25 mg) of aluminum
- The FDA limit for aluminum in injectable products is 850 micrograms per dose
- A single dose is well within this regulatory limit
- Aluminum adjuvants have been used in vaccines since the 1930s

*The mainstream position:* Medical authorities consider the amount of aluminum in vaccines safe based on decades of use, toxicokinetic studies, and the fact that infants are exposed to more aluminum through breast milk and formula than through vaccines. The body processes and excretes small amounts of aluminum routinely.

*The concerns raised:*
- Aluminum is a known neurotoxin at high doses
- Injected aluminum is processed differently by the body than ingested aluminum (injected aluminum bypasses the gut, which normally blocks most dietary aluminum absorption)
- Critics argue that current safety margins were not established with newborn body weight and developing brains specifically in mind
- Some researchers have raised questions about whether cumulative aluminum exposure across the infant vaccine schedule (which includes multiple aluminum-containing vaccines) has been adequately studied
- A 2011 study by Tomljenovic and Shaw published in the _Journal of Inorganic Biochemistry_ raised concerns about aluminum adjuvant accumulation, though its methodology has been criticized

*The honest summary:* Mainstream medicine considers the aluminum content safe. A smaller but vocal group of researchers and clinicians believes the safety evidence — particularly for cumulative exposure in young infants — has gaps. Reasonable people can disagree on whether the current evidence is sufficient, especially for a vaccine given at birth against a disease the baby is unlikely to encounter.

=== VAERS: The Vaccine Adverse Event Reporting System

VAERS is the primary post-market surveillance system for vaccines in the United States. It is co-managed by the CDC and the FDA. Understanding what VAERS is and is not helps put vaccine safety discussions in context.

*What VAERS is:*
- A passive reporting system where anyone — doctors, nurses, parents, or patients — can submit reports of health events that occur after vaccination
- It is designed to detect potential safety signals that may not have appeared in pre-licensure trials
- It has detected real safety signals, including intussusception with the rotavirus vaccine (leading to its withdrawal) and myocarditis associated with COVID-19 mRNA vaccines

*What VAERS is not:*
- Reports to VAERS do not prove causation. A report means an event occurred after vaccination — not that the vaccine caused it
- Reports are not verified or investigated before being entered into the database
- Because anyone can file, the quality and accuracy of individual reports varies widely

*Why some parents reference it:*
- VAERS contains thousands of reports associated with the hepatitis B vaccine, including serious adverse events and deaths
- For parents researching vaccine safety, these reports are visible and concerning

*Balanced framing:* VAERS data alone does not prove vaccines caused any particular reported event. However, dismissing all VAERS reports as meaningless is not intellectually honest either. VAERS is the tool the government built to monitor vaccine safety after licensure — it is imperfect, but it is the primary system we have. When it shows clusters of similar reports, those signals warrant investigation. Whether any given signal reflects a real causal relationship is a question that requires further study, and that further study does not always happen as quickly or thoroughly as parents might expect.

#line(length: 100%)

== Making Your Decision

=== Questions to Consider

*About your hepatitis B status:*
- Do you know your screening results? When were you tested?
- Are you confident in the accuracy of your results?

*About household risk:*
- Do any household members have known hepatitis B infection?
- Has everyone in your household been tested?
- Are household members vaccinated?

*About your values and risk assessment:*
- How do you weigh the near-zero risk of exposure (for HBV-negative families) against the vaccine's safety profile?
- Do you have concerns about aluminum adjuvant exposure in a newborn?
- If you plan to vaccinate, do you have reliable access to follow-up care to complete the series?

=== Factors That Favor the Birth Dose

Proceed with the birth dose if:
- You have not been tested for hepatitis B or your status is unknown
- You test positive for hepatitis B
- A household member has hepatitis B or unknown status
- You use injection drugs or have household members who do
- You will travel to areas with higher hepatitis B rates
- You are uncomfortable with any delay in protection

=== Factors That May Support Delaying

Delay may make sense for your family if:
- You have been reliably tested and confirmed negative during this pregnancy
- All household members are tested negative or vaccinated
- You have reliable access to follow-up care
- You prefer to begin the series when the baby is older

=== Factors That May Support Declining

Declining entirely may make sense for your family if:
- Both parents have tested negative for hepatitis B
- All household members are tested negative or vaccinated
- You assess your child's lifetime risk of hepatitis B exposure as very low
- You have concerns about the vaccine's adjuvant content or the level of safety evidence
- You prefer to revisit the decision when your child is older and circumstances may have changed
- You follow an alternative or delayed vaccine schedule

=== How to Communicate Your Decision

Whatever you decide, here is how to communicate it clearly.

*If you choose to delay to 2 months — sample language for your birth plan:*

> "We decline the Hepatitis B vaccine at this time. I am Hepatitis B negative. We plan to begin the vaccine series at the 2-month well-baby visit."

*If you choose to delay to a later age — sample language:*

> "We decline the Hepatitis B vaccine at this time. I am Hepatitis B negative. We will revisit this vaccine at a later age based on our family's risk assessment."

*If you choose to decline entirely — sample language:*

> "We decline the Hepatitis B vaccine. Both parents are Hepatitis B negative. We have made this decision after reviewing the transmission routes, our family's risk factors, and the vaccine's safety profile."

*Steps to take:*

1. *Know your hepatitis B test results* before delivery
2. *Document* your decision in writing in your birth plan
3. *Communicate* your decision to hospital staff when you arrive — clearly and early
4. *Be prepared* for pushback. Some nurses or pediatricians may pressure you. You do not owe anyone a justification. A simple, firm "this is our informed decision" is sufficient.

*Know your rights:* Vaccination decisions are legally yours to make as a parent. Every US state allows medical exemptions, and most allow religious or philosophical exemptions for childhood vaccines. You do not need your provider's permission to decline. Having your negative test results documented can help smooth the conversation with hospital staff.

=== If You Choose the Birth Dose

Your newborn will receive a single injection in the thigh within the first 24 hours of life. Common mild side effects include soreness at the injection site or mild fever. Two additional doses will be scheduled at 1-2 months and 6-18 months.

#line(length: 100%)

== Our Take

The hepatitis B vaccine decision comes down to a fundamental question: *does your newborn face a meaningful risk of hepatitis B exposure?*

If the answer is yes — if you are HBV-positive, if your status is unknown, or if household members may carry the virus — the birth dose is a clear and important intervention. The data on perinatal transmission is stark, and the vaccine is highly effective at preventing chronic infection in exposed newborns.

If the answer is no — if you and your partner are confirmed HBV-negative and your household has no known risk factors — then you are weighing the benefits of a "just in case" intervention against whatever concerns you have about giving it to a newborn.

*What we want you to know:*

Hepatitis B is transmitted through blood and sexual contact. It is not floating in the air at the grocery store. For a newborn with HBV-negative parents, the actual risk of exposure in infancy is extremely low — not "low" in the way that rare complications are low, but effectively zero unless specific and unlikely circumstances arise.

The birth dose was adopted in 1991 partly because hospitals provide a "captive audience" where vaccination can be guaranteed — not because there is medical urgency for day-one protection in low-risk babies. The United States was an outlier among developed nations: countries like Japan, Sweden, and the UK achieved excellent hepatitis B outcomes without universal birth dosing.

There are legitimate questions about the safety evidence. The vaccine has not been tested in true placebo-controlled trials against an inert control. It contains aluminum adjuvant, and reasonable people disagree about whether the existing safety data adequately addresses newborn exposure. The primary post-market surveillance tool (VAERS) has limitations that cut both ways — it cannot prove causation, but it also should not be dismissed entirely.

*All of these are valid paths:*

- *Vaccinate at birth* because you value the safety net, you trust the observational safety record, and you want protection from day one
- *Delay to 2 months* because you want to give your newborn a gentler start while still vaccinating on a schedule close to the CDC recommendation
- *Delay to school age or pre-adolescence* because you assess the risk as negligible during early childhood and prefer to vaccinate closer to when actual exposure risk begins
- *Decline entirely* because you have evaluated your family's risk profile and concluded the vaccine is not necessary for your child

None of these choices is negligent. All of them reflect a parent weighing real information and making a judgment call for their family. We trust you to make that call.

*If you do choose to vaccinate at any point,* the three-dose series is effective regardless of when it starts. A child vaccinated at 5 years old achieves the same immunity as one vaccinated at birth.

*If you choose not to vaccinate,* know that hepatitis B risk can be revisited at any point in your child's life — before international travel, before adolescence, or whenever circumstances change.

#line(length: 100%)

== Key Sources

- #link("https://www.cdc.gov/media/releases/2025/2025-hepatitis-b-immunization.html")[CDC: Hepatitis B Immunization Individual-Based Decision-Making]
- #link("https://www.cdc.gov/vaccine-safety/vaccines/hepatitis-b.html")[CDC: Hepatitis B Vaccine Safety]
- #link("https://www.cdc.gov/hepatitis-b/hcp/perinatal-provider-overview/index.html")[CDC: Perinatal Hepatitis B Overview]
- #link("https://www.aap.org/en/news-room/fact-checked/fact-checked-hepatitis-b-vaccine-given-to-newborns-reduces-risk-of-chronic-infection/")[American Academy of Pediatrics: Fact Check on Hepatitis B Vaccine]
- #link("https://publichealth.jhu.edu/2025/why-hepatitis-b-vaccination-begins-at-birth")[Johns Hopkins: Why Hepatitis B Vaccination Begins at Birth]
- #link("https://www.who.int/news-room/fact-sheets/detail/hepatitis-b")[WHO: Hepatitis B Fact Sheet]
- #link("https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-b-virus-infection-in-pregnant-women-screening")[USPSTF: Hepatitis B Screening in Pregnancy]
- #link("https://www.hepb.org/prevention-and-diagnosis/transmission/")[Hepatitis B Foundation: Transmission and Prevention]
- #link("https://vaers.hhs.gov/")[VAERS: Vaccine Adverse Event Reporting System]
- #link("https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/vaccine-adverse-event-reporting-system-vaers")[FDA: About VAERS]
- #link("https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878266/")[Tomljenovic & Shaw: Aluminum Vaccine Adjuvants — Are They Safe?]
